Strategic Partnership Eremid collaborates with industry leaders like BioSkryb, providing opportunities to co-market and co-develop service offerings such as long-read multiomics, which can unlock joint sales by combining capabilities with potential clients in single-cell and ultra-low-input research.

Early Access Programs The recent launch of an Early Access Program for BioSkryb ResolveSEQ LongRead indicates a receptiveness to innovative sequencing solutions; target prospects with high curiosity for new technologies and offer trialed integrations or pilot projects to accelerate scope and engagement.

Growth Stage Signals With a revenue range of one to ten million and a $3M funding round, Eremid is positioned as a growing boutique CRO; target mid-market biotech and agritech firms seeking specialized, high-complexity genomics services with flexible engagement models.

Multi-Sector Focus Eremid serves Human Health, Food & Nutrition, and AgBiotech, suggesting cross-industry sales plays; craft tailored pitches showing how genomics platforms can address regulatory-ready data, multi-omics integrations, and rapid data delivery across diverse programs.

Operational Readiness The company’s emphasis on expert consultancy, transparent timelines, proactive updates, and on-time data delivery signals a strong service mindset; leverage this to position value-based proposals that emphasize risk reduction, project governance, and predictable milestones for prospects.